cyrilzakka/clinical-trials huggingface dataset:
A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease

The primary objective of this preliminary study is to investigate whether the transcranial direct current stimulation (tDCS) improves the cognitive function in patients with Alzheimer's disease

Twenty patients were recruited and randomized to receive either real or sham-tDCS over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC). Their legally responsible caregivers were provided with mobile tDCS device, and were instructed to use it on the patients at home. 30-minute session of the stimulation were applied everyday in the morning for 12 weeks. The patients were evaluated at baseline, at week 6 and 12.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who have Korean version of Mini Mental Status Examination score 10 to 24
* Subjects who have SVLT and RCFT delayed recall test scores lower than 1.5SD
* Subjects who have had other cognitive impairments besides memory
* Subjects who have Seoul-Instrumental Activities of Daily Living score (S-IADL) of 8 or more.
* Subjects who are only dementia of Alzheimer's type
* Subjects who are right-handed
* Subjects who are able to read and write
* Both patient and legally responsible caregiver has provided informed consent
* According to the latest MRI result, periventricular white matter cap or band is less than 10mm, or the deep white matter hyper-intensity is less than 25 mm

Exclusion Criteria:

* Subjects who have a history of stroke and seizures
* Subjects who have any illnesses that may disturb the patients completing the trials, including stroke, Parkinson's disease, type 1 diabetes, uncontrollable high blood pressure, Huntington's disease, cerebral palsy, liver failure, nephritis, encephalitis, meningitis, scleroma, seizures and a transient ischemic attack.
* Subjects who have a History of DSM-IV Axis I disorders
* Subjects who have neurologic problems on physical examination that cause memory disturbances
* Subjects who have Extremely sensitive skin
* Subjects who have suffered from the cancer in 3 years
* Subjects who have had a cerebrovascular neurosurgery in medical history
* Subjects who have dyspnea in sitting position
* Subjects who have problems with memory, language and problem-solving for 2 hours after the heart attack.
* Subjects who have a history of drug or alcohol abuse (in the past 5 years)
* Subjects who have a history of mental or emotional disorders (in the past 5 years)
* Subjects who have been lapsed into unconsciousness for an hour because of other reasons than general anesthesia
* Subjects who have a history of hospitalization due to head injury
* Subjects who are unable to read even with glasses
* Subjects who are unable to understand the conversation due to the hearing defect (even with the hearing aid)
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world practice settings.

The study population consisted of patients with histologically confirmed stage IIIB, IIIC, or IV MET Exon 14 skipping mutated NSCLC with BM. The date of the initiation of therapy with capmatinib after the date of initial BM diagnosis at or after the initial advanced or metastatic NSCLC diagnosis defined the study index date. The 12-month period before the study index date defined the baseline period to assess baseline demographic and clinical characteristics. Study measures were assessed at the index and during the baseline and postindex date periods. The index date needed to occur between 1 May 2020 and the date of data abstraction, provided the selected patients meet the requirement of a minimum of 6 months follow-up time available after capmatinib initiation; the exceptions to this are those patients who died during this period.


Eligibility Criteria:
Inclusion Criteria

* Patient was aged ≥ 18 years at the time of NSCLC diagnosis
* Patient had histologically confirmed stage IIIB, IIIC, or IV NSCLC with MET Exon 14 skipping mutation at the time of initial NSCLC diagnosis
* Patient had ≥ 1 measurable intracranial lesion after initial diagnosis of BM
* Patient was treated with capmatinib after diagnosis of BM (any line)

Exclusion Criteria

* Patients with characterized Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations that predict sensitivity to epidermal growth factor receptor therapy, including but not limited to exon 19 deletions and exon 21 mutations
* Patients with other known actionable molecular alterations (such as ROS1 translocation or BRAF mutation) who might be candidates to receive alternative targeted therapies
* Patients who had been treated with METis in any therapy line before or after the study index date
* Patients who had participated in a clinical trial related to treatment for NSCLC at any time before or after the study index date
FAST Mapping During Atrial Fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide with a prevalence of 8% in the elderly. AF is responsible for frequent hospitalizations, stroke, heart failure and mortality. AF catheter ablation is an important treatment strategy for patients suffering from AF, but the success rate remains low after conventional pulmonary vein isolation (PVI). The mechanism perpetuating AF is poorly understood. Focal electrical sources and triggers (FAST) may sustain AF in some patients, which makes them a potential therapeutic target for ablation. However, finding FAST is very challenging due to complex nature of AF electrical signals. In this study, the investigators will attempt to localize focal electrical sources and triggers (FAST mapping) in patients undergoing AF ablation using custom software that evaluates periodicity and waveform morphology. Patients will be randomized to one of two AF ablation strategies, namely FAST mapping/ablation + PVI vs. PVI alone. The investigators will determine which strategy leads to better clinical outcome postablation.


Eligibility Criteria:
Inclusion Criteria:

* All patients must be over the age 18 and have a clinical indication for their first catheter ablation of AF because of symptomatic AF.
* This will include patients with either high burden paroxysmal (\>4 self-terminating episodes of AF within the last 6 months with two episodes lasting at least 6 hours within the last year) or persistent AF (lasting ≥7 days, but which can still be converted to sinus rhythm).

Exclusion Criteria:

* The major exclusion criteria will include:

  * long-standing persistent AF (ie. AF which cannot be converted to sinus rhythm, or where multiple attempts at restoring sinus rhythm have failed)
  * rheumatic valvular disease
  * hypertrophic cardiomyopathy
  * uncorrected cardiac shunts (eg. secundum ASD)
  * severe mitral regurgitation or mechanical mitral valve
  * left atrial size \>55 mm (echo derived parasternal long axis view).
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics

In a sample of patients already receiving ketamine treatment as part of their clinical care, this project seeks to test whether we can enhance and/or extend ketamine's rapid effects by introducing helpful information delivered by a computer-based cognitive training protocol. This work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.


Eligibility Criteria:
Inclusion Criteria:

1. be between the ages of 18 and 80 years
2. score ≥20 on the Montgomery-Asberg Depression Rating Scale (MADRS)
3. per SCID-5-RV interview, meet DSM-5 diagnostic criteria for at least one of the following: Major Depressive Disorder, Bipolar Disorder (I or II), Persistent Depressive Disorder, or Other Specified Depressive or Bipolar Disorder
4. exhibit treatment resistance, defined as: (a) failure to respond to ≥1 adequate trials of an evidence-based treatment for mood disorder \[per the Antidepressant Treatment History Form-Short Form Modified Score Sheet (ATHF-SF-Modified)\] and/or (b) failure to respond to ≥1 adequate mood stabilizer or other evidence-based treatment trials (for bipolar depression patients) and/or (c) a history of intolerance during attempted trials of evidence-based treatments for mood disorders
5. be eligible and clinically enrolled for upcoming IV ketamine at one of our study clinics according to that clinic's standard intake procedures
6. agree to maintain a stable schedule of concomitant psychiatric medications throughout the ketamine induction phase (minor adjustments to PRN meds and timing of meds are allowable), and for 4 weeks post-induction phase
7. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document
8. be willing and able to provide names and contact information for at least 1 additional emergency contact in the patient's proximal geographic area (in addition to the ketamine treatment team at the enrolling site)

Exclusion Criteria:

1. Presence of current/acute psychosis, mania, or dementia, or a diagnosis of developmental disorder with significant language and/or intellectual impairment (e.g., autism spectrum disorder)
2. Current/acute suicide risk with intent to act, defined as CSSRS past-week ideation score ≥ 4 among outpatients; patients engaged in residential or inpatient care at the time of enrollment need not meet this CSSRS score criterion, as their current/acute suicide risk is extremely low by virtue of the residential/inpatient, round-the-clock care they are already receiving at time of enrollment
3. Concern for dementia or significant cognitive decline, per interviewer observations and impressions during screening assessments
4. Current pregnancy or breastfeeding
5. English reading level \<5th grade as per patient self-report Rationale: to ensure adequate reading comprehension for verbal ASAT/sham stimuli which are presented in English
Can Making Video Narratives Benefit Adolescents With Cancer

The purpose of this study is to learn more about the content of and benefits of making video testimonials in adolescents with cancer.

The current research aims to:

A. enlist teens with cancer to produce video narratives about their experiences with their illness B. explicitly characterize and investigate the videos' content and C. determine what aspects of the production were helpful to the teen making them and predicted to be helpful to those watching them.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with cancer
* Patients receiving cancer treatment for the first time
* Can complete study before high school graduation
* Must be able to read and understand English

Exclusion Criteria:

* Participants cannot have been treated for other chronic illnesses prior to cancer diagnosis
* Patients with cognitive and.or verbal capacities impaired to the point where they cannot consent or assent for themselves
* Patients who cannot communicate narratives clearly due to cognitive and/or verbal impairments
Tab Block and Patient Controlled Analgesia in CS

cesarean section rate become increasing nowadays

indication of cesarean section are different from case to case and the use of pain controlling agents is very important to relieve post operative pain

Eligibility Criteria:
Inclusion Criteria:

* women coming for an elective CS

Exclusion Criteria:

* women who has a n emergency CS or complicated normal deivery needs urgent CS
Mild Carpal Tunnel Syndrome

Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment. Diagnosis is based on symptoms, clinical findings and electrophysiological examination. Several conservative and surgical treatment options have been described.

Studies of surgical versus conservative treatment in mild carpal tunnel syndrome have not been done and it is still unclear whether or not surgical treatment is better than conservative treatment.

The aim of this study is to research has surgery better outcome in mild CTS than conservative treatment. Patient satisfactory, clinical and electrophysiologic outcomes, direct and indirect costs will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* electrophysiologically proven minimal or mild CTS lasting more than six months will be included in this study

Exclusion Criteria:

* rheumatoid arthritis
* diabetes mellitus
* hypothyreosis
* pregnancy
* wrist trauma or previous surgery
* splinting or corticosteroid injection on the affected side
Reference Values for Respiratory Resistance Measured by the Interrupter Technique in Adults

The purpose is to obtain reference values of respiratory resistance (a technique widely used in children), in adults. The interest is that this technique needs only little co-operation and would be particularly adapted in subjects in whom co-operation is insufficient for other measurements.


Eligibility Criteria:
Inclusion Criteria:

* Adult non smokers, without any disease interfering with pulmonary function
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.

Original French title of the study: Etude de phase IV, multicentrique, randomisée, ouverte, comparant les réactions et la douleur aux sites d'injection après administration sous-cutanée d'interféron β-1b (Betaferon®) ou interféron β-1a (Rebif®) pendant la période de trois mois d'initiation de la thérapie chez des patients atteints d'une forme récurrente/rémittente de sclérose en plaques.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.

Eligibility Criteria:
Inclusion Criteria:

* Males or females
* Age \>= 18 years old
* Patients after a first demyelinating event suggestive of MS (only for Betaferon) as well as patients with a definite diagnosis of RRMS (Betaferon et Rebif)
* First justified prescription of one interferon beta by subcutaneous route (as described in Summary of Product Characteristics \[SmPC\] of Betaferon or Rebif)
* Females of child-bearing potential must agree to practice adequate contraceptive methods over the duration of the study (not applicable for men)
* Patient can follow and comply with all study procedures of the trial protocol
* Laboratory evaluations (i.e., evaluation of hepatic enzyme gamma-GT, full blood count and differential white blood cell count \[WBC\]) must be available and the results must be normal.
* Written informed consent

Exclusion Criteria:

* Any contraindication to the prescription of Betaferon or Rebif, as described in the SmPC of products:

  * Pregnancy or lactation
  * Known hypersensitivity to natural or recombinant interferon beta, to mannitol, to human albumin or any other excipients used
  * History of severe depression or suicide attempt or current suicidal ideation.
  * Patient with decompensated liver disease
  * Epilepsy not adequately controlled by treatment
* Patient previously included in this study.
* Patient previously treated by sub-cutaneous route with either Betaferon or Rebif.
* Participation in any clinical trial within the past 30 days involving the investigational drug intake.
* Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol or to complete the study.
Speech, Linguistic and Acoustic Markers in Parkinson's Disease

The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.


Eligibility Criteria:
Inclusion Criteria:

* Parkinson's Disease (or healthy control)
* Disease duration ≥ 2 years
* Mild cognitive impairment or normal cognition

Exclusion Criteria:

* Diagnosis of dementia (MoCA \<21)
* Adults unable to consent
* Age \< 18
* Pregnant women
* Prisoners
* Non-English speakers
* Any neurological disorder other than PD
* Deep brain stimulator placement
* Severe, unstable psychiatric disorder
* Unintelligible speech due to effects of PD
* Visual acuity or color vision impairment that would interfere with cognitive testing
* Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords
Bosutinib For Autosomal Dominant Polycystic Kidney Disease

This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or equal to 750 cc and eGFR greater than or equal to 60 mL/min/1.73m2.


Eligibility Criteria:
Inclusion Criteria:

* Males and females, 18 to 50 years old at the time of consent.
* Documented diagnosis of ADPKD (PKD-1 or PKD-2 genotypes allowed).
* Total kidney volume ≥ 750 cc, as measured by centrally evaluated MRI.

Exclusion Criteria:

* eGFR \< 60 mL/min/1.73m2.
* Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg).
* Any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (PKD) therapies.
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of D-TACE for patients in Advanced Unresectable HCC. The investigators previous study also revealed similar results in Advanced Unresectable HCC patients treated with D-TACE. Recently, the investigators previous study demonstrated that, compared with D-TACE, hepatic arterial infusion chemotherapy (HAIC) may improve tumor response in Advanced Unresectable HCC. Thus, the investigators carried out this prospective nonrandomized control to demonstrate the superiority of HAIC-based combination therapy over D-TACE-based combination therapy.

HCC is one of the most common malignant tumors with the worst prognosis. At present, except for liver transplantation, surgical resection is the most effective therapy for patients with HCC. However, many patients are found to have advanced cancer as soon as they were diagnosed and lose the opportunity of radical resection and treatments are limited.More and more clinical research failures have hit the investigators' hard, until a clinical study named IMbrave150, published in the New England Journal of Medicine in 2020. It has opened up a new era of combination therapy, breaking the pattern of only a single mode of advanced liver cancer for more than ten years, making the investigators realize that for the treatment of patients with advanced liver cancer, the single treatment effect is often very limited, and combination therapy is the future.The investigators recent research showed that HAIC Combined With Lenvatinib and Tislelizumab brings good results to patients with advanced HCC.To identify a more effective and safety way for treating potentially resectable HCC patients, this study is designed to compare the safety and efficacy between HAIC-based combination therapy and D-TACE-based combination therapy for those patients in Advanced Unresectable HCC.

Eligibility Criteria:
Inclusion Criteria:

* Patients with advanced unresectable hepatocellular carcinoma treated by D- TACE, or HAIC combined with Lenvatinib and Tislelizumab as initial treatment
* Age between 18 and 75 years
* Child-Pugh A or B liver function
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Adequate hematologic blood counts (white blood cell count \>3ⅹ109/L, absolute neutrophil count \>1.5ⅹ109/L, platelet count \>10ⅹ109/L, hemoglobin concentration \>85 g/L
* No extrahepatic metastasis

Exclusion Criteria:

* Severe underlying cardiac, pulmonary, or renal diseases
* History of a second primary malignant tumor
* Incomplete medical data
* Loss to follow-up.
Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.

The purpose of this research study is to compare the effectiveness of a sphenopalatine ganglion block to an epidural blood patch for post-dural puncture headache relief in randomized postpartum parturients over a 48 hour period.

The purpose of this research study is to compare the effectiveness of a sphenopalatine ganglion block to an epidural blood patch for post-dural puncture headache relief in randomized postpartum parturients over a 48 hour period. A known dural puncture is defined as free flow of cerebral spinal fluid (CSF) during neuraxial placement. An unknown dural puncture is defined as neuraxial placement where free flow of CSF is not appreciated, however the patient is diagnosed with a post-dural puncture headache as defined by the International Classification of Headache Disorders.

Eligibility Criteria:
Inclusion Criteria

1. Age 18 years or age or greater
2. Postpartum obstetric parturient who was previously admitted to UCH.
3. Diagnosis of post-dural puncture headache based on the International Classification of Headache Disorders:

   1. Dural puncture has been performed
   2. Headache has developed within 5 days of the dural puncture
   3. Not better accounted for by another ICHD-3 diagnosis.
   4. Occurring immediately or within seconds of assuming an upright position and resolving quickly (within 1 minute) after lying horizontally.

Exclusion Criteria

1. Refusal to participate in the study
2. Placement of an EBP within the past 5 days
3. Allergy and/or intolerance to any the study materials
4. Contraindications to an EBP
5. Plan for therapeutic anticoagulation post-partum